Seeking Alpha

Gentium (GENT -1%) announces an agreement with National University, Hamamatsu University School...

Gentium (GENT -1%) announces an agreement with National University, Hamamatsu University School of Medicine, Fukushima Medical University and LINK Healthcare to support a Phase I clinical trial of its Defibrotide anti-clotting drug candidate. Under the terms of the agreement, (GENT) will provide free drug and technical support and LINK will provide administrative and logistical support for the clinical trial conducted by HUSM.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)